Danish global healthcare company LEO Pharma has entered into an asset purchase agreement with Japanese pharmaceutical firm Astellas Pharma to acquire its global dermatology business for €675m.

The dermatology portfolio of Astellas comprises of both prescription and over-the-counter (OTC) products, including Protopic, Locoid and Locobase, and Zineryt to treat eczema, acne and skin infections.

Subject to the satisfaction of customary closing conditions, including review and approval by competition authorities, the transaction is scheduled to be completed in the first quarter of next year.

"This is a historic milestone for LEO Pharma and will be instrumental in our efforts to help even more people living with skin diseases."

According to LEO, the transaction does not include any manufacturing facilities of Astellas.

Once the dermatology portfolio is fully transferred, annual turnover of LEO Pharma is estimated to increase by more than 20%.

LEO Pharma CEO and president Gitte Aabo said: "This is a historic milestone for LEO Pharma and will be instrumental in our efforts to help even more people living with skin diseases.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"With our expanded portfolio, we will be able to offer patients an even wider range of treatment solutions to meet their individual needs."

The acquisition will create a strong foothold for LEO in the Chinese and Russian markets as well as adds critical scale in many other markets.

Astellas Pharma president and CEO Yoshihiko Hatanaka said: "We feel that dermatology patients around the world will be better served by transferring these products to LEO Pharma, a company with a strong focus on the dermatology therapeutic area."

LEO is focused on developing, manufacturing and marketing pharmaceutical drugs to dermatologic and thrombotic patients in more than 100 countries.

The company has its own sales forces in 61 countries and employs around 4,800 people across the globe.

Upon completion of the acquisition, both the firms will jointly work to ensure a smooth and effective transition of the products and business to LEO Pharma.